login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
APIMEDS PHARMACEUTICALS US I (APUS) Stock News
USA
- NYSEARCA:APUS -
US03771D1028
-
Common Stock
3.21
USD
+0.42 (+15.05%)
Last: 11/14/2025, 8:04:00 PM
3.09
USD
-0.12 (-3.74%)
After Hours:
11/14/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APUS Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
a month ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
2 months ago - By: Benzinga
- Mentions:
PDEX
IRWD
ENTA
SCYX
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 months ago - By: Benzinga
- Mentions:
SNGX
ANTX
CHEK
ADAP
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
2 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
2 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
3 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
4 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
6 months ago - By: ACCESS Newswire
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering
6 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
6 months ago - By: Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Please enable JavaScript to continue using this application.